spacer
home > pmps > winter 2019 > a new phase of hope
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A New Phase of Hope

The global pharmaceutical industry has entered an exciting new era of drug development, bringing new hope to patients around the world. Close to 40% of all medicines in pipeline development are estimated to be biologic in nature.

The worldís top-selling commercial biologic medicines cover a broad range of diseases (including autoimmune challenges such as various forms of arthritis and psoriasis, Crohnís disease, ankylosing spondylitis, ulcerative colitis, and other conditions such as multiple sclerosis and macular degeneration), bringing hope to many long-suffering patients.

Biologic medicines have also transformed treatment and personal care for a significant portion of the diabetes patient population. Furthermore, biologics have provided breakthrough therapies in the advanced treatment for various forms of cancer, where more than 70 new therapies have entered the market within the past five years, many of which are biologic in nature.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Justin Schroeder is Senior Executive Director of Global Marketing and Design at PCI Pharma Services, with over 20 yearsí experience in outsourced pharma services in various roles, including engineering, project management, marketing, and development.
spacer
Justin Schroeder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New Report Introduces Benchmarks on Clinical Trials Vendor Qualification Process

PRINCETON, NJ ‚Äď A new report from Tufts Center for the Study of Drug Development establishes benchmarks for the vendor qualification process, a critical element of clinical trial set up and execution. According to its November/December Impact Report, the process volume and complexity of the vendor qualification process creates delays in initiation in 7% of clinical trials for biopharma sponsors and 14% of trials for Contract Research Organizations.
More info >>

White Papers

Tabletability, Compactability, and Compressibilty: Whatís the Difference?

Natoli Engineering Company, Inc.

To patients and consumers, tablets are a simple and convenient dosage form. But the science behind compressing a block of particles or granules into a single tablet can be complicated. Thatís where common compression studies can help. This article explains how to develop tabletability, compactibility, and compressibility profiles.
More info >>

 
Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement